Eli Lil­ly posts promis­ing PhI­II mi­graine re­sults, but set­tles in­to the pack in the last leg of the race to the FDA

Eli Lil­ly $LLY is lin­ing up its ap­pli­ca­tion for its CGRP mi­graine drug gal­canezum­ab af­ter rack­ing up a slate of date from three Phase III stud­ies that puts it right along­side its many ri­vals. The head­line suc­cess was her­ald­ed weeks ago, with the de­tails un­veiled Sat­ur­day at the Amer­i­can Headache So­ci­ety an­nu­al sci­en­tif­ic meet­ing in Boston.

CGRP drugs look like a safe way to low­er the num­ber of mi­graine days per month among pa­tients with episod­ic and chron­ic mi­graine, the 120 mg and 240 mg dos­es of gal­canezum­ab cut the av­er­age num­ber of de­bil­i­tat­ing episodes by 4 and 3.8 days in one study for episod­ic mi­graine and 3.7 days and 3.6 days in an­oth­er — com­pared to a place­bo re­sponse that ran from 1.85 to 2.15 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER